Neurodegenerative Diseases: Current Research
Volume 4 (2024) 2 Pages
DOI: https://dx.doi.org/10.53043/NDCR-4-001

Short Article | *Open Access*

Exploring Necrosis, Astrocytes, and Anti-IgLON5 Disease: Unraveling Links in Neurodegenerative Disorders

K.N Reddy*

Independent researcher, Kenilworth, England, UK

***Correspondence:** K.N Reddy, Independent researcher, Kenilworth, England, UK E-Mail: nagtdd@gmail.com

Received: February 21, 2024;

Accepted: March 25, 2024;

Published: April 11, 2024

Citation: K.N Reddy, Exploring Necrosis, Astrocytes, and Anti-IgLON5 Disease: Unraveling Links in Neurodegenerative Disorders. Neurodegener Dis Current Res. (2024);4(1): 1-2

Key words: Necrosis, Astrocytes, Anti-IgLON5 disease, Neurodegeneration, Tauopathy, Necroptosis, Glial cells, Neuroinflammation.

Abstract

Neurodegenerative diseases, characterized by the progressive loss of neuronal function, are increasingly linked to intricate cellular and molecular mechanisms. Among these, astrocytes, essential glial cells in the central nervous system (CNS), and necrotic pathways have emerged as pivotal players in disease progression. Anti-IgLON5 disease, a unique neurodegenerative disorder with both autoimmune and tauopathy features, provides a novel context to examine these interactions. This article explores the role of necrosis and astrocyte dysfunction in the pathophysiology of anti-IgLON5 disease, shedding light on broader implications for neurodegenerative diseases. Insights into these mechanisms could pave the way for innovative therapeutic strategies targeting glial cells and necrotic processes.

1. Introduction

Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and anti-IgLON5 disease, share pathological hallmarks such as protein aggregation, neuroinflammation, and neuronal death [1,4]. A critical but underexplored aspect of these disorders is the role of necrosis—a form of cell death characterized by membrane rupture and the release of inflammatory mediators (Yuan et al. 19). Astrocytes, which maintain CNS homeostasis, are increasingly implicated in neurodegenerative pathology. Anti-IgLON5 disease, marked by sleep disturbances, tau protein deposition, and autoantibodies against IgLON5, provides a unique framework to understand how necrosis and astrocyte dysfunction contribute to neurodegeneration [5].

Necrosis in Neurodegenerative Diseases Necrosis is traditionally viewed as an uncontrolled process; however, recent evidence reveals regulated necrotic pathways, such as necroptosis, play critical roles in CNS pathology [6]. In neurodegenerative diseases, necrosis contributes to:

- **Inflammation**: Release of damage-associated molecular patterns (DAMPs) exacerbates neuroinflammation [1].

- **Tissue damage**: Propagation of cell death impairs neuronal networks.
- **Astrocyte activation**: Necrotic cell debris activates astrocytes, potentially leading to reactive gliosis and loss of supportive functions [3].

Astrocyte Dysfunction in Anti-IgLON5 Disease Astrocytes are essential for synaptic support, neurotransmitter regulation, and blood-brain barrier maintenance. In anti-IgLON5 disease, astrocytes exhibit dual roles:

- **Pathological contributors**: Astrocytes may exacerbate tauopathy by failing to clear tau aggregates or by secreting pro-inflammatory cytokines [7].
- **Victims of necrosis**: Astrocytes themselves may undergo necrotic death, amplifying CNS damage.

Studies highlight altered astrocytic signaling in anti-IgLON5 disease, with increased expression of inflammatory mediators such as interleukin-1β and tumor necrosis factor-α. Astrocytic necrosis also releases glutamate, contributing to excitotoxicity and neuronal injury [4].

Interplay Between Necrosis and Astrocytes Necrosis and astrocyte dysfunction form a feedback loop in anti-IgLON5 disease:

1. **Necrotic signaling**: Tau aggregates and autoantibodies induce necrosis, releasing inflammatory mediators [2].
2. **Astrocyte activation**: Activated astrocytes amplify inflammation and tauopathy [3].
3. **Progressive degeneration**: Sustained necrosis and astrocyte dysfunction drive neuronal loss [5].

Therapeutic Implications Targeting the interplay between necrosis and astrocytes offers promising therapeutic avenues:

- **Inhibitors of necroptosis**: Molecules such as necrostatins may prevent necrosis-driven inflammation [6].
- **Astrocyte modulators**: Drugs restoring astrocytic functions or reducing reactive gliosis, such as ceftriaxone, could mitigate disease progression.
- **Immunotherapies**: Approaches targeting IgLON5 autoantibodies may reduce immune-mediated astrocyte damage [6].

2. Conclusion

Necrosis and astrocyte dysfunction are central to the pathology of anti-IgLON5 disease and other neurodegenerative disorders. Understanding their interplay provides a deeper insight into disease mechanisms and highlights novel therapeutic targets. Future research should focus on elucidating these pathways in detail and developing targeted interventions to alleviate the burden of neurodegenerative diseases.

3. References

1. Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's Disease. *The Lancet Neurology*, vol. 14, no. 4, 2015, pp. 388-405.
2. Karch C M, Goate AM Alzheimer's Disease Risk Genes and Mechanisms of Disease Pathogenesis. *Biological Psychiatry*, vol. 77, no. 1, 2015, pp. 43-51.
3. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia. *Nature*, vol. 541, no. 7638, 2017, pp. 481-487.
4. Ransohoff RM How Neuroinflammation Contributes to Neurodegeneration. *Science*, vol. 353, no. 6301, 2016, pp. 777-783.
5. Sabater, L. Neuropathological Criteria of Anti-IgLON5-Related Tauopathy. *Acta Neuropathologica*, vol. 132, no. 4, 2016, pp. 531-543.
6. Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1-Mediated Neuroinflammation in CNS Diseases. *Nature Reviews Neuroscience*, vol. 20, no. 1, 2019, pp. 19-33.
7. Zhang Y, Wu KM, Yang L, Dong Q, Yu JT Trojanowski. Tauopathies: New Perspectives and Challenges. *Molecular Neurodegeneration*, vol. 17, no. 28, 2022, pp. 1-12.